Clinical Trial Detail

NCT ID NCT03684811
Title A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Forma Therapeutics, Inc.
Indications

liver carcinoma

malignant glioma

chondrosarcoma

hepatocellular carcinoma

Advanced Solid Tumor

bile duct carcinoma

biliary tract cancer

intrahepatic cholangiocarcinoma

Therapies

Cisplatin + Gemcitabine + Olutasidenib

Azacitidine + Olutasidenib

Olutasidenib

Nivolumab + Olutasidenib

Age Groups: adult senior

Additional content available in CKB BOOST